Literature DB >> 20142040

Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant.

Nicolas Basse1, Joel L Kaar, Giovanni Settanni, Andreas C Joerger, Trevor J Rutherford, Alan R Fersht.   

Abstract

The p53 cancer mutation Y220C induces formation of a cavity on the protein's surface that can accommodate stabilizing small molecules. We combined fragment screening and molecular dynamics to assess the druggability of p53-Y220C and map ligand interaction sites within the mutational cavity. Elucidation of the binding mode of fragment hits by crystallography yielded a clear picture of how a drug might dock in the cavity. Simulations that solvate the protein with isopropanol found additional sites that extend the druggable surface. Moreover, structural observations and simulation revealed the dynamic landscape of the cavity, which improves our understanding of the impact of the mutation on p53 stability. This underpins the importance of considering flexibility of the cavity in screening for optimized ligands. Our findings provide a blueprint for the design of effective drugs that rescue p53-Y220C. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20142040     DOI: 10.1016/j.chembiol.2009.12.011

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  39 in total

Review 1.  SCF ubiquitin ligase-targeted therapies.

Authors:  Jeffrey R Skaar; Julia K Pagan; Michele Pagano
Journal:  Nat Rev Drug Discov       Date:  2014-11-14       Impact factor: 84.694

2.  Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding.

Authors:  Joel L Kaar; Nicolas Basse; Andreas C Joerger; Elaine Stephens; Trevor J Rutherford; Alan R Fersht
Journal:  Protein Sci       Date:  2010-12       Impact factor: 6.725

3.  Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery.

Authors:  Hernani Leonardo Silvestre; Thomas L Blundell; Chris Abell; Alessio Ciulli
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-19       Impact factor: 11.205

Review 4.  Enhanced interrogation: emerging strategies for cell signaling inhibition.

Authors:  Rong Huang; Isabel Martinez-Ferrando; Philip A Cole
Journal:  Nat Struct Mol Biol       Date:  2010-06       Impact factor: 15.369

5.  Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.

Authors:  Sara Calhoun; Valerie Daggett
Journal:  Biochemistry       Date:  2011-05-17       Impact factor: 3.162

Review 6.  Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases.

Authors:  Vladimir N Uversky; Vrushank Davé; Lilia M Iakoucheva; Prerna Malaney; Steven J Metallo; Ravi Ramesh Pathak; Andreas C Joerger
Journal:  Chem Rev       Date:  2014-05-15       Impact factor: 60.622

Review 7.  Driving Structure-Based Drug Discovery through Cosolvent Molecular Dynamics.

Authors:  Phani Ghanakota; Heather A Carlson
Journal:  J Med Chem       Date:  2016-08-17       Impact factor: 7.446

8.  Ordering a dynamic protein via a small-molecule stabilizer.

Authors:  Ningkun Wang; Chinmay Y Majmudar; William C Pomerantz; Jessica K Gagnon; Jack D Sadowsky; Jennifer L Meagher; Taylor K Johnson; Jeanne A Stuckey; Charles L Brooks; James A Wells; Anna K Mapp
Journal:  J Am Chem Soc       Date:  2013-02-22       Impact factor: 15.419

9.  The p53-MDM2/MDMX axis - A chemotype perspective.

Authors:  Kareem Khoury; Grzegorz M Popowicz; Tad A Holak; Alexander Dömling
Journal:  Medchemcomm       Date:  2011       Impact factor: 3.597

Review 10.  Drugging the p53 pathway: understanding the route to clinical efficacy.

Authors:  Kian Hoe Khoo; Khoo Kian Hoe; Chandra S Verma; David P Lane
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.